Glucoryl-MP2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Pioglitazone 15mg, formulated as a sustained-release tablet for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control without causing significant hypoglycemia. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The combined action of these agents addresses multiple pathophysiological defects in type 2 diabetes, offering effective glycemic control with a reduced risk of adverse effects compared to monotherapy. Glucoryl-MP2 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on monotherapy or dual therapy. The sustained-release formulation ensures a gradual release of active ingredients, enhancing patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Therapy should be individualized, and regular monitoring of blood glucose, renal function, and liver enzymes is recommended during treatment.